GRAND PHARMA (00512) Income Statement & Earnings

6.220
-0.190-2.96%

Market Closed Apr 30 16:07 CST

22.08BMarket Cap17.77P/E (TTM)

GRAND PHARMA (00512) Income Statement

All

YOY

Hide blank lines

(FY)Dec 31, 2025

(Q6)Jun 30, 2025

(FY)Dec 31, 2024

(Q6)Jun 30, 2024

(FY)Dec 31, 2023

(Q6)Jun 30, 2023

(FY)Dec 31, 2022

(Q6)Jun 30, 2022

(FY)Dec 31, 2021

(Q6)Jun 30, 2021

Turnover

5.48%12.28B

0.99%6.11B

10.59%11.64B

0.96%6.05B

10.12%10.53B

14.90%5.99B

11.22%9.56B

14.15%5.21B

35.34%8.6B

40.26%4.57B

Operating income

5.48%12.28B

0.99%6.11B

10.59%11.64B

0.96%6.05B

10.12%10.53B

14.90%5.99B

11.22%9.56B

14.15%5.21B

35.34%8.6B

40.26%4.57B

Cost of sales

-12.15%-5.5B

-2.09%-2.51B

-22.50%-4.91B

-15.79%-2.46B

-10.93%-4.01B

-8.63%-2.12B

-7.76%-3.61B

-16.66%-1.95B

-44.57%-3.35B

-37.73%-1.67B

Operating expenses

-12.15%-5.5B

-2.09%-2.51B

-22.50%-4.91B

-15.79%-2.46B

-10.93%-4.01B

-8.63%-2.12B

-7.76%-3.61B

-16.66%-1.95B

-44.57%-3.35B

-37.73%-1.67B

Gross profit

0.62%6.78B

0.25%3.6B

3.28%6.74B

-7.16%3.59B

9.62%6.52B

18.66%3.87B

13.42%5.95B

12.70%3.26B

30.04%5.25B

41.77%2.89B

Selling expenses

-16.89%-3.81B

-18.88%-1.92B

-26.84%-3.26B

1.57%-1.61B

-11.32%-2.57B

-19.27%-1.64B

3.81%-2.31B

2.94%-1.37B

-28.91%-2.4B

-48.06%-1.41B

Administrative expenses

-1.74%-1.39B

-14.11%-691.75M

-10.61%-1.37B

12.89%-606.2M

-13.24%-1.23B

-26.35%-695.89M

-19.83%-1.09B

-28.34%-550.76M

-32.74%-909.62M

-39.62%-429.15M

Revaluation surplus

-129.19%-189.31M

-60.66%174.59M

451.71%648.55M

93.22%443.75M

314.11%117.55M

158.50%229.66M

-111.52%-54.9M

-231.34%-392.56M

75.56%476.5M

5,081.53%298.89M

-Changes in the fair value of derivative financial instruments

----

12.71%-27.38M

----

-178.98%-31.37M

----

575.69%39.72M

----

---8.35M

----

-Changes in the fair value of financial assets

-128.01%-189.31M

-60.66%174.59M

353.88%675.93M

93.22%443.75M

257.38%148.92M

158.50%229.66M

-119.52%-94.62M

-231.34%-392.56M

78.64%484.85M

5,081.53%298.89M

Impairment and provision

68.38%-38.72M

----

22.23%-122.45M

----

-1,072.83%-157.45M

---59.65M

-3,703.12%-13.43M

----

98.02%-353K

----

-Goodwill impairment

----

-25.39%-49.07M

----

-7.39%-39.14M

----

---36.44M

----

-Other impairment is provision

47.23%-38.72M

----

37.98%-73.38M

----

-614.04%-118.32M

---59.65M

6,620.40%23.02M

----

98.02%-353K

----

Special items of operating profit

-7.33%224.01M

147.42%203.58M

324.22%241.73M

131.75%82.28M

-150.96%-107.81M

-409.81%-259.14M

-39.38%211.57M

36.67%83.64M

-9.00%349.02M

-35.97%61.2M

Operating profit

-45.20%1.58B

-27.85%1.37B

12.02%2.88B

31.36%1.9B

-4.59%2.57B

40.73%1.45B

-2.41%2.7B

-27.09%1.03B

29.99%2.76B

62.46%1.41B

Financing cost

9.93%-162.34M

6.70%-80.35M

12.14%-180.24M

23.94%-86.12M

-49.20%-205.15M

-79.13%-113.23M

-47.90%-137.49M

-167.05%-63.21M

19.46%-92.96M

59.27%-23.67M

Share of profits of associates

-48.86%76.06M

207.95%57.94M

694.69%148.72M

376.26%18.82M

42.89%-25.01M

85.92%-6.81M

-138.46%-43.79M

-308.46%-48.38M

83.71%113.86M

-62.66%23.21M

Earning before tax

-47.62%1.49B

-26.42%1.35B

21.68%2.85B

38.18%1.83B

-6.86%2.34B

44.77%1.33B

-9.65%2.52B

-34.99%915.7M

34.35%2.79B

61.66%1.41B

Tax

35.34%-249.78M

28.73%-174.02M

13.92%-386.3M

9.20%-244.18M

-7.19%-448.76M

-23.49%-268.93M

-9.94%-418.64M

-6.60%-217.78M

-30.24%-380.8M

-23.44%-204.3M

After-tax profit from continuing operations

-49.54%1.24B

-26.07%1.17B

30.10%2.47B

50.24%1.59B

-9.67%1.9B

51.42%1.06B

-12.76%2.1B

-42.04%697.92M

35.02%2.41B

70.62%1.2B

Earning after tax

-49.54%1.24B

-26.07%1.17B

30.10%2.47B

50.24%1.59B

-9.67%1.9B

51.42%1.06B

-12.76%2.1B

-42.04%697.92M

35.02%2.41B

70.62%1.2B

Minority profit

248.19%3.43M

-83.70%4.85M

-115.00%-2.32M

8.55%29.76M

-17.99%15.44M

319.55%27.42M

662.74%18.83M

-837.19%-12.49M

121.56%2.47M

113.35%1.69M

Profit attributable to shareholders

-49.73%1.24B

-24.96%1.17B

31.30%2.47B

51.35%1.56B

-9.59%1.88B

44.90%1.03B

-13.45%2.08B

-40.92%710.41M

34.02%2.4B

67.37%1.2B

Basic earnings per share

-49.72%0.3544

-24.84%0.3338

31.51%0.7049

52.51%0.4441

-8.69%0.536

44.44%0.2912

-13.32%0.587

-40.50%0.2016

30.16%0.6772

59.29%0.3388

Diluted earnings per share

-49.72%0.3544

-24.84%0.3338

31.51%0.7049

52.51%0.4441

-8.69%0.536

44.44%0.2912

-13.32%0.587

-40.50%0.2016

30.16%0.6772

59.29%0.3388

Currency Unit

HKD

Accounting Standards

HKAS

Audit Opinions

Unqualified Opinion

Auditor

National Health Accounting Firm Co., Ltd.

	(FY)Dec 31, 2025	(Q6)Jun 30, 2025	(FY)Dec 31, 2024	(Q6)Jun 30, 2024	(FY)Dec 31, 2023	(Q6)Jun 30, 2023	(FY)Dec 31, 2022	(Q6)Jun 30, 2022	(FY)Dec 31, 2021	(Q6)Jun 30, 2021
Turnover	5.48%12.28B	0.99%6.11B	10.59%11.64B	0.96%6.05B	10.12%10.53B	14.90%5.99B	11.22%9.56B	14.15%5.21B	35.34%8.6B	40.26%4.57B
Operating income	5.48%12.28B	0.99%6.11B	10.59%11.64B	0.96%6.05B	10.12%10.53B	14.90%5.99B	11.22%9.56B	14.15%5.21B	35.34%8.6B	40.26%4.57B
Cost of sales	-12.15%-5.5B	-2.09%-2.51B	-22.50%-4.91B	-15.79%-2.46B	-10.93%-4.01B	-8.63%-2.12B	-7.76%-3.61B	-16.66%-1.95B	-44.57%-3.35B	-37.73%-1.67B
Operating expenses	-12.15%-5.5B	-2.09%-2.51B	-22.50%-4.91B	-15.79%-2.46B	-10.93%-4.01B	-8.63%-2.12B	-7.76%-3.61B	-16.66%-1.95B	-44.57%-3.35B	-37.73%-1.67B
Gross profit	0.62%6.78B	0.25%3.6B	3.28%6.74B	-7.16%3.59B	9.62%6.52B	18.66%3.87B	13.42%5.95B	12.70%3.26B	30.04%5.25B	41.77%2.89B
Selling expenses	-16.89%-3.81B	-18.88%-1.92B	-26.84%-3.26B	1.57%-1.61B	-11.32%-2.57B	-19.27%-1.64B	3.81%-2.31B	2.94%-1.37B	-28.91%-2.4B	-48.06%-1.41B
Administrative expenses	-1.74%-1.39B	-14.11%-691.75M	-10.61%-1.37B	12.89%-606.2M	-13.24%-1.23B	-26.35%-695.89M	-19.83%-1.09B	-28.34%-550.76M	-32.74%-909.62M	-39.62%-429.15M
Revaluation surplus	-129.19%-189.31M	-60.66%174.59M	451.71%648.55M	93.22%443.75M	314.11%117.55M	158.50%229.66M	-111.52%-54.9M	-231.34%-392.56M	75.56%476.5M	5,081.53%298.89M
-Changes in the fair value of derivative financial instruments	----	----	12.71%-27.38M	----	-178.98%-31.37M	----	575.69%39.72M	----	---8.35M	----
-Changes in the fair value of financial assets	-128.01%-189.31M	-60.66%174.59M	353.88%675.93M	93.22%443.75M	257.38%148.92M	158.50%229.66M	-119.52%-94.62M	-231.34%-392.56M	78.64%484.85M	5,081.53%298.89M
Impairment and provision	68.38%-38.72M	----	22.23%-122.45M	----	-1,072.83%-157.45M	---59.65M	-3,703.12%-13.43M	----	98.02%-353K	----
-Goodwill impairment	----	----	-25.39%-49.07M	----	-7.39%-39.14M	----	---36.44M	----	----	----
-Other impairment is provision	47.23%-38.72M	----	37.98%-73.38M	----	-614.04%-118.32M	---59.65M	6,620.40%23.02M	----	98.02%-353K	----
Special items of operating profit	-7.33%224.01M	147.42%203.58M	324.22%241.73M	131.75%82.28M	-150.96%-107.81M	-409.81%-259.14M	-39.38%211.57M	36.67%83.64M	-9.00%349.02M	-35.97%61.2M
Operating profit	-45.20%1.58B	-27.85%1.37B	12.02%2.88B	31.36%1.9B	-4.59%2.57B	40.73%1.45B	-2.41%2.7B	-27.09%1.03B	29.99%2.76B	62.46%1.41B
Financing cost	9.93%-162.34M	6.70%-80.35M	12.14%-180.24M	23.94%-86.12M	-49.20%-205.15M	-79.13%-113.23M	-47.90%-137.49M	-167.05%-63.21M	19.46%-92.96M	59.27%-23.67M
Share of profits of associates	-48.86%76.06M	207.95%57.94M	694.69%148.72M	376.26%18.82M	42.89%-25.01M	85.92%-6.81M	-138.46%-43.79M	-308.46%-48.38M	83.71%113.86M	-62.66%23.21M
Earning before tax	-47.62%1.49B	-26.42%1.35B	21.68%2.85B	38.18%1.83B	-6.86%2.34B	44.77%1.33B	-9.65%2.52B	-34.99%915.7M	34.35%2.79B	61.66%1.41B
Tax	35.34%-249.78M	28.73%-174.02M	13.92%-386.3M	9.20%-244.18M	-7.19%-448.76M	-23.49%-268.93M	-9.94%-418.64M	-6.60%-217.78M	-30.24%-380.8M	-23.44%-204.3M
After-tax profit from continuing operations	-49.54%1.24B	-26.07%1.17B	30.10%2.47B	50.24%1.59B	-9.67%1.9B	51.42%1.06B	-12.76%2.1B	-42.04%697.92M	35.02%2.41B	70.62%1.2B
Earning after tax	-49.54%1.24B	-26.07%1.17B	30.10%2.47B	50.24%1.59B	-9.67%1.9B	51.42%1.06B	-12.76%2.1B	-42.04%697.92M	35.02%2.41B	70.62%1.2B
Minority profit	248.19%3.43M	-83.70%4.85M	-115.00%-2.32M	8.55%29.76M	-17.99%15.44M	319.55%27.42M	662.74%18.83M	-837.19%-12.49M	121.56%2.47M	113.35%1.69M
Profit attributable to shareholders	-49.73%1.24B	-24.96%1.17B	31.30%2.47B	51.35%1.56B	-9.59%1.88B	44.90%1.03B	-13.45%2.08B	-40.92%710.41M	34.02%2.4B	67.37%1.2B
Basic earnings per share	-49.72%0.3544	-24.84%0.3338	31.51%0.7049	52.51%0.4441	-8.69%0.536	44.44%0.2912	-13.32%0.587	-40.50%0.2016	30.16%0.6772	59.29%0.3388
Diluted earnings per share	-49.72%0.3544	-24.84%0.3338	31.51%0.7049	52.51%0.4441	-8.69%0.536	44.44%0.2912	-13.32%0.587	-40.50%0.2016	30.16%0.6772	59.29%0.3388
Currency Unit	HKD	HKD	HKD	HKD	HKD	HKD	HKD	HKD	HKD	HKD
Accounting Standards	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS	HKAS
Audit Opinions	--	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--	Unqualified Opinion	--
Auditor	--	--	National Health Accounting Firm Co., Ltd.	--	National Health Accounting Firm Co., Ltd.	--	National Health Accounting Firm Co., Ltd.	--	National Health Accounting Firm Co., Ltd.	--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"